Lenalidomide Capsule - Antitumor agent, immunomodulator, which possesses both immunomodulatory and antiangiogenic properties.

Inhibits the secretion of proinflammatory cytokines, including TNFα, interleukin-1β (IL-1β), IL-6 and IL-12, from liposaccharide (LPS) -stimulated peripheral blood mononuclear cells (PMCC).

Lenalidomide increases the production of the anti-inflammatory cytokine IL-10 from LPS-stimulated PMCC, as a result of which inhibition of the expression, but not the enzymatic activity of COX-2, occurs.

Lenalidomide induces the proliferation of T-cells and increases the synthesis of IL-2 and interferon gamma-1, and also increases the cytotoxic activity of its own killer cells.

Lenalidomide inhibits the proliferation of cells of various hematopoietic tumor lines, mainly those that have cytogenetic defects of chromosome 5.

On the model of erythroid progenitor cell differentiation, lenalidomide induces the expression of fetal hemoglobin, judging by the differentiation of CD34 stem hematopoietic cells.

Lenalidomide Cost inhibits angiogenesis by blocking the formation of microvessels and endothelial channels, as well as the migration of endothelial cells in an in vitro model of angiogenesis. In addition, lenalidomide inhibits the synthesis of proangiogenic vascular endothelial growth factor by PC-3 prostate tumor cells.